文献速递类风湿关节炎

抗CCP抗体阳性伴肌肉骨骼症状的高危个体中超声亚临床滑膜炎:类风湿关节炎连续谱中的重要且可预测阶段

Ultrasound subclinical synovitis in anti-CCP-positive at-risk individuals with musculoskeletal symptoms: an important and predictable stage in the rheumatoid arthritis continuum.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

在抗CCP2阳性伴肌肉骨骼症状但无临床滑膜炎的高危个体中,77.3%(75/97)的进展者在发生炎症性关节炎前可检测到超声亚临床滑膜炎,中位时间26.5周;基线超声正常者中31.4%(69/220)后续出现超声滑膜炎,仅抗CCP3抗体为预测因素(OR 4.75)。

要点

  • 抗CCP2阳性高危个体中,亚临床滑膜炎常先于炎症性关节炎出现,中位间隔26.5周。
  • 基线超声正常者中31.4%后续出现超声滑膜炎,中位时间56.4周。
  • 多变量分析仅抗CCP3抗体预测超声滑膜炎发生(OR 4.75,95%CI 1.97–11.46,P<0.01)。

核心结论

  • 在抗CCP2阳性高危个体中,亚临床滑膜炎阶段通常先于炎症性关节炎发生。
  • 抗CCP2阳性/CCP3阳性且无临床或超声亚临床滑膜炎的个体,可能是干预以预防关节疾病的最佳机会窗口。

研究设计与样本

  • 回顾性分析抗CCP2阳性伴肌肉骨骼症状但无临床滑膜炎的高危个体的超声扫描,排除进展前>6个月超声阴性者后评估亚临床滑膜炎。
  • 对基线超声无异常、至少有一次纵向超声扫描且数据集完整的抗CCP2阳性高危个体进行回归分析以识别超声滑膜炎预测因素。

主要发现

  • 97例进展者中75例(77.3%)在一次或多次扫描中检测到超声亚临床滑膜炎,从首次证据至炎症性关节炎发生的中位时间26.5周(IQR 7–60)。
  • 220例基线超声正常的抗CCP2阳性高危个体中,69例(31.4%)检测到超声滑膜炎,至首次出现的中位时间56.4周(IQR 33.0–112.0)。
  • 多变量分析中,仅抗CCP3抗体预测超声滑膜炎发生,OR 4.75(95%CI 1.97–11.46),P<0.01。

关键数值与推荐

  • 进展者亚临床滑膜炎检出率77.3%(75/97),中位至炎症性关节炎时间26.5周(IQR 7–60)。
  • 基线超声正常者超声滑膜炎检出率31.4%(69/220),中位至首次检出时间56.4周(IQR 33.0–112.0)。
  • 抗CCP3抗体预测超声滑膜炎的OR 4.75(95%CI 1.97–11.46),P<0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether anti-CCP2-positive at-risk individuals with musculoskeletal (MSK) symptoms but without clinical synovitis (CCP2+ at-risk) develop US subclinical synovitis before inflammatory arthritis and if US subclinical synovitis can be predicted. METHODS: First, US scans of CCP2+ at-risk individuals who developed inflammatory arthritis ('progressors') were reviewed for subclinical synovitis prior to inflammatory arthritis development. Patients in whom the pre-progression US scan was negative but the scan was conducted >6 months before progression were excluded. Subsequently, regression analyses were performed to identify predictors of US synovitis in CCP2+ at-risk individuals without baseline US abnormalities who had one or more longitudinal US scan and a complete dataset. RESULTS: US subclinical synovitis was detected in one or more scan in 75 of 97 progressors (77.3%) {median time to inflammatory arthritis development from first evidence of US synovitis 26.5 weeks [interquartile range (IQR) 7-60]}, in whom one or more scan was available, excluding those with a negative scan >6 months from inflammatory arthritis development (n = 38). In 220 CCP2+ at-risk individuals with normal baseline US scans, who had one or more longitudinal US scan and a complete dataset, US synovitis was detected in 69/220 (31.4%) [median time to first developing US synovitis 56.4 weeks (IQR 33.0-112.0)]. In the multivariable analysis, only anti-CCP3 antibodies were predictive for the development of US synovitis [odds ratio 4.75 (95% CI 1.97, 11.46); P < 0.01]. CONCLUSIONS: In anti-CCP2+ at-risk individuals, a stage of subclinical synovitis usually precedes the development of inflammatory arthritis. Anti-CCP2+/CCP3+ individuals without clinical or US subclinical synovitis may represent the optimal window of opportunity for intervention to prevent joint disease.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Di Matteo A, Duquenne L, Cipolletta E, et al. Ultrasound subclinical synovitis in anti-CCP-positive at-risk individuals with musculoskeletal symptoms: an important and predictable stage in the rheumatoid arthritis continuum. Rheumatology (Oxford). 2022. PMID: 34849610. doi:10.1093/rheumatology/keab862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。